Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | FURIN | P09958 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22349913 | 1.00 | HRH1 (0.38) | HRH1CASP1CTSLNMT2NMT1 | |
| SCHEMBL20381011 | 0.91 | CASP1 (0.40) | HRH1CASP1PTGS1PTGS2 | |
| SCHEMBL22349949 | 0.91 | CASP1 (0.40) | HRH1CASP1PTGS1PTGS2 | |
| SCHEMBL19776913 | 0.89 | NMT2 (0.39) | HRH1CTSLNMT2NMT1FURIN | |
| SCHEMBL20349812 | 0.89 | NMT2 (0.39) | HRH1CTSLNMT2NMT1FURIN | |
| SCHEMBL20287715 | 0.89 | NMT2 (0.35) | NMT2NMT1PTGS1PTGS2SLC6A5 | |
| SCHEMBL17860180 | 0.89 | HRH1 (0.38) | HRH1CASP1CTSLNMT2NMT1 | |
| SCHEMBL22134316 | 0.86 | HRH1 (0.39) | HRH1CASP1CTSLNMT2NMT1 | |
| SCHEMBL17860164 | 0.86 | HRH1 (0.39) | HRH1CASP1CTSLNMT2NMT1 | |
| SCHEMBL20287648 | 0.86 | HRH1 (0.39) | HRH1CASP1CTSLNMT2NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | KIF5B, KIF23, KIF2C | HRH1 3205/4885CASP1 4544/4885CTSL 3798/4885 |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | HRH1 462/4885CASP1 4673/4885CTSL 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.